Nelfinavir

Research use only, not for human use.

A potent and orally bioavailable HIV-1 protease inhibitor with Ki of 2 nM.

A potent and orally bioavailable HIV-1 protease inhibitor with Ki of 2 nM; exhibits an antiviral EC50 of 30 nM in HIV-1 strain RF-infected CEM-SS cells; also inhibits the proliferation of NSCLC cells, as well as every cell line in the NCI60 cell line panel with mean GI50 of 5.2 uM, induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.HIV Infection Approved.

Cell Proliferation AssayCell Line:RPMI, LP1, U266, OPM2 and MM1S cells Concentration:1, 2, 5, 10 μM Incubation Time:48 hours Result:Inhibited the proliferation of RPMI, LP1, U266, OPM2 and MM1S cell lines in a dose-dependent manner with an IC50 of 1-5 μM. Apoptosis Analysis Cell Line:LP1 and U266 cells Concentration:1-10 μM Incubation Time:17 hours Result:Induced a dose-dependent increase in the percentage of annexin V+/propidium iodide+ cells. Western Blot Analysis Cell Line:U266 cells Concentration:5 μM Incubation Time:0-24 hours Result:The level of AKT phosphorylation in U266 cells decreased.

Animal Model:NOD/SCID mice (bearing U266-luc cells) Dosage:75 mg/kg Administration:I.p.; 5 days a week for 21 days Result:Decreased MM cell growth in NOD/SCID mice.

AG-1343

Microbiology/Virology

HIV

HIV

Infection

HIV Infection

159989-64-7

567.784

C32H45N3O4S

>98% (HPLC)

DMSO : ≥ 25 mg/mL. 44.03 mM

CC1=C(C=CC=C1O)C(=O)NC(CSC2=CC=CC=C2)C(CN3CC4CCCCC4CC3C(=O)NC(C)(C)C)O

——

(-20℃)

With Ice Pack

≥ 2 years